A Phase 2 interventional study of CP-675,206 (Tremelimumab) in Colorectal Neoplasms, Melanoma and Prostatic Neoplasms, sponsored by AstraZeneca. Completed at 6 sites in 2 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-08-22.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing tremelimumab in Colorectal Neoplasms — 1 open to participants now, 2 under way, none of them phase 3. tremelimumab · Colorectal Neoplasms.
Among the 14 studies testing tremelimumab in Colorectal Neoplasms, this one is the 6th largest by enrollment, is the only one that started in 2007, is one of 8 in phase 2, and was the 2nd registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →1 of the 14 studies testing tremelimumab in Colorectal Neoplasms is open now, in 1 country. Recruiting first, the newest first:
Anwaar Saeed · Sites in United States
Ages 18+
By country, each count listing its studies:
tremelimumab: first FDA approval 2022 (IMJUDO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, tremelimumab is the treatment under test here. Read study by study →
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10
First in 2006; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 34 across the 14 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 14 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
29 studies in Colorectal Neoplasms by AstraZeneca: 2 open now, 8 under way, none of them phase 3. Of 19 finished, 7 (37%) have results posted.
Among the 29 studies in Colorectal Neoplasms by AstraZeneca, this one is the 20th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2007, is one of 12 in phase 2, and was the 7th registered.
AstraZeneca’s Colorectal Neoplasms studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing tremelimumab in Colorectal Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 29 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study is intended to provide access to tremelimumab for patients who have previously received tremelimumab in a clinical trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: CP-675,206 (Tremelimumab)
Drug: CP-675,206 (Tremelimumab)
15 mg/kg IV every 3 months as long as required
Also known as: anti-CTLA4 human monoclonal antibody
Safety Endpoints: Serious Adverse Events to Tremelimumab.
Time frame: Following the first dose, until at least 90 days since the previous dose of tremelimumab or at least 28 days since any study-related procedures. Actual median study duration was 2.2 years.
Safety Endpoints: Grade 3 or 4 Tremelimumab-related Adverse Events to Tremelimumab.
Time frame: Following the first dose, until at least 90 days since the previous dose of tremelimumab or at least 28 days since any study-related procedures. Actual median study duration was 2.2 years.
Safety Endpoints: Hypersensitivity Reactions to Tremelimumab.
Time frame: Following the first dose, until at least 90 days since the previous dose of tremelimumab or at least 28 days since any study-related procedures. Actual median study duration was 2.2 years.
Efficacy Endpoints: Tumor Status: Alive With Disease (AWD) or no Evidence of Disease (NED)
Time frame: Following the first dose, until at least 90 days since the previous dose of tremelimumab or at least 28 days since any study-related procedures. Actual median study duration was 2.2 years.
Efficacy Endpoints: Survival
Time frame: Following the first dose, until at least 90 days since the previous dose of tremelimumab or at least 28 days since any study-related procedures. Actual median study duration was 2.2 years.
Disease Free Survival
Time from the first dose of study drug to the earliest date of evidence of disease (based on tumor status assessment) or death, whichever occurred first
Time frame: Following the first dose, until at least 90 days since the previous dose of tremelimumab or at least 28 days since any study-related procedures. Actual median study duration was 2.2 years.
First subject enrolled: 05 Mar 2007; Data Cut-off: 18 Jun 2020. This was a multicenter study conducted at 11 study centers in 3 countries (the United Kingdom, the United States of America and Italy).
| Milestone | Tremelimumab 15mg/kg |
|---|---|
| Started | 37 |
| Completed | 6 |
| Not completed | 31 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Lack of efficacy | 8 |
| Withdrew: Subject or physician decision, or subject relocation to another city or region. | 9 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Adverse event | 9 |
| Participants | Tremelimumab 15mg/kg |
|---|---|
| Number of Participants with SAE to tremelimumab | 4 |
| Number of Participants with no SAE to tremelimumab | 33 |
| Participants | Tremelimumab 15mg/kg |
|---|---|
| Number of participants with Grade 3 or 4 tremelimumab-related adverse events to tremelimumab | 4 |
| Number of participants with no Grade 3 or 4 tremelimumab-related adverse events to tremelimumab | 33 |
| Participants | Tremelimumab 15mg/kg |
|---|---|
| Number of participants with Hypersensitivity reactions to tremelimumab | 6 |
| Number of participants with no Hypersensitivity reactions to tremelimumab | 31 |
| Participants | Tremelimumab 15mg/kg |
|---|---|
| No evidence of disease | 19 |
| Evidence of disease | 17 |
| Indeterminate | 1 |
| Participants | Tremelimumab 15mg/kg |
|---|---|
| Death | 10 |
| Censored | 27 |
Time from the first dose of study drug to the earliest date of evidence of disease (based on tumor status assessment) or death, whichever occurred first
| Days | Tremelimumab 15mg/kg |
|---|---|
| Disease Free Survival | 3.0 (2.9 to 11.8) |
Collected over 13 years, 3 months. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tremelimumab 15mg/kg | 11/37 (29.7%) | 4/37 (10.8%) | 5/37 (13.5%) |
| Event | Tremelimumab 15mg/kg |
|---|---|
| DiarrheaGastrointestinal disorders | 1/37 |
| Medical Device ComplicationGeneral disorders | 1/37 |
| CholecystitisHepatobiliary disorders | 1/37 |
| SepsisInfections and infestations | 1/37 |
| Urinary Tract InfectionInfections and infestations | 1/37 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/37 |
| Pulmonary GranulomaRespiratory, thoracic and mediastinal disorders | 1/37 |
| Event | Tremelimumab 15mg/kg |
|---|---|
| RashSkin and subcutaneous tissue disorders | 4/37 |
| PruritusSkin and subcutaneous tissue disorders | 3/37 |
| HypothyroidismEndocrine disorders | 2/37 |
One participant received no study medication and was excluded from data analysis
| Age, Categorical(Participants) | Tremelimumab 15mg/kg |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 24 |
| >=65 years | 13 |
| Sex: Female, Male(Participants) | Tremelimumab 15mg/kg |
|---|---|
| Female | 11 |
| Male | 26 |
| Race (NIH/OMB)(Participants) | Tremelimumab 15mg/kg |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 37 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Mar 2007 to primary completion in Oct 2023, 199 months.
Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 199 months is above that.
Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tremelimumab